Affiliation:
1. Translational Molecular Biomarkers and
2. Translational Medicine, Genzyme Corporation, Cambridge, MA
3. Translational Pharmacology, Merck Research Laboratories, Rahway, NJ
Abstract
Abstract
BACKGROUND
Biomarkers are important tools in drug development and are used throughout pharmaceutical research.
CONTENT
This review focuses on molecular biomarkers in drug development. It contains sections on how biomarkers are used to assess target engagement, pharmacodynamics, safety, and proof-of-concept. It also covers the use of biomarkers as surrogate end points and patient selection/companion diagnostics and provides insights into clinical biomarker discovery and biomarker development/validation with regulatory implications. To survey biomarkers used in drug development—acknowledging that many pharmaceutical development biomarkers are not published—we performed a focused PubMed search employing “biomarker” and the names of the largest pharmaceutical companies as keywords and filtering on clinical trials and publications in the last 10 years. This yielded almost 500 entries, the majority of which included disease-related (approximately 60%) or prognostic/predictive (approximately 20%) biomarkers. A notable portion (approximately 8%) included HER2 (human epidermal growth factor receptor 2) testing, highlighting the utility of biomarkers for patient selection. The remaining publications included target engagement, safety, and drug metabolism biomarkers. Oncology, cardiovascular disease, and osteoporosis were the areas with the most citations, followed by diabetes and Alzheimer disease.
SUMMARY
Judicious biomarker use can improve pharmaceutical development efficiency by helping to select patients most appropriate for treatment using a given mechanism, optimize dose selection, and provide earlier confidence in accelerating or discontinuing compounds in clinical development. Optimal application of biomarker technology requires understanding of candidate drug pharmacology, detailed modeling of biomarker readouts relative to pharmacokinetics, rigorous validation and qualification of biomarker assays, and creative application of these elements to drug development problems.
Publisher
Oxford University Press (OUP)
Subject
Biochemistry (medical),Clinical Biochemistry
Reference75 articles.
1. Clinical development success rates for investigational drugs;Hay;Nat Biotechnol,2014
2. Can the pharmaceutical industry reduce attrition rates?;Kola;Nat Rev Drug Discov,2004
3. Diagnosing the decline in pharmaceutical R&D efficiency;Scannell;Nat Rev Drug Discov,2012
4. US Food and Drug Administration. Challenges and opportunities report: March 2004. http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm (Accessed January 2015).
5. Dako. Interpretation manual: breast cancer. http://www.dako.com/28630_herceptest_interpretation_manual-breast_ihc_row.pdf (Accessed January 2015).
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献